Perioperative acute renal failure

Current Opinion in Anaesthesiology

Volumn 19, Issue 3, 2006, Pages 332-338

  Mahon, Padraig ^a   Shorten, George ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

Biomarkers; Perioperative; Renal failure; Reperfusion

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOUBLE STRANDED RNA; FENOLDOPAM MESILATE; FUROSEMIDE; HUMAN GROWTH HORMONE; NUCLEOTIDE; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; RECOMBINANT SOMATOMEDIN C; UNCLASSIFIED DRUG; URODILANTIN;

ACUTE KIDNEY FAILURE; ANESTHESIOLOGICAL TECHNIQUES; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CRUSH TRAUMA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EDEMA; ELECTROPORATION; ENDOTHELIUM CELL; EPIDEMIOLOGICAL DATA; EXPERIMENTAL RAT; GENE THERAPY; GENE TRANSFER; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART SURGERY; HUMAN; IN VITRO STUDY; INCIDENCE; ISCHEMIC PRECONDITIONING; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; LIVER FAILURE; MICROTHROMBUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OBSTRUCTION; PATHOPHYSIOLOGY; PERFUSION PRESSURE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; RISK FACTOR; SEPSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; HUMANS; KIDNEY FAILURE, ACUTE; POSTOPERATIVE COMPLICATIONS; RATS; RISK FACTORS;

EID: 33744973765     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000192819.76353.b3     Document Type: Review

References (73)

1. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcome of acute renal failure. Lancet 2000; 365:26-30.
2. Bellomo R, Ronco C, Kellum JA, et al. and the ADQI Workgroup. Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212.
3. Jarnberg PO. Renal protective strategies in the perioperative period. Best Pract Res Clin Anaesthesiol 2004; 18:645-660.
4. Liano F, Pascual J, The Madrid Acute Renal Failure Study Group. Epidemiology of acute renal failure: a prospective, multicentre, community-based study. Kidney Int 1996; 50:811-818.
5. Anderson RJ, O'Brien M, MaWhinney S, et al. Mild renal failure is associated with adverse outcome after cardiac valve surgery. Am J Kidney Dis 2000; 35:1127-1134.
6. Chertow GM, Levy EM, Hammermeister KE, et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104:343-348.
7. Carmichael P, Carmichael AR. Acute renal failure in the surgical setting. Aust N Z J Surg 2003; 73:144-153.
8. Reddy VG. Prevention of postoperative acute renal failure. J Postgrad Med 2002; 48:64-70.
9. Swanninathana M, Stafford-Smith M. Renal dysfunction after vascular surgery. Curr Opin Anaesthesiol 2003; 16:45-51.
10. Metnitz PG, Krenn CG, Stelzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30:2051-2058.
11. Conlon P, Stafford-Smith M, White W, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 1999; 14:1158-1162.
12. Blantz RC. Pathophysiology of pre-renal azotaemia. Kidney Int 1998; 54:2051-2058.
13. Kohli HS, Bhaskaran MC, Muthukumar T, et al. Treatment-related acute renal failure in the elderly: a hospital based prospective study. Nephrol Dial Transplant 2000; 15:212-217.
14. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischaemic acute renal failure. J Am Soc Nephrol 2003; 14:2199-2210.
15. Conger JD, Weil JV. Abnormal vascular function following ischaemia-reperfusion injury. J Investig Med 1995; 43:431-442.
16. Ruschitzka F, Shaw S, Gygi D, et al. Endothelial dysfunction in acute renal failure: role of circulating and tissue endothelin. J Am Soc Nephrol 1999; 10:953-962.
17. Reinhart K, Bayer O, Brunkhorst F, et al. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30 (Suppl.):S302-S312.
18. Yamada K, Miwa T, Liu J, et al. Cortical protection from renal ischaemia reperfusion injury by CD55 and CD59. J Immunol 2004; 172:3869-3875.
19. Lien YH, Lai LW, Silva AL. Pathogenesis of renal ischemia/reperfusion: Lessons from knockout mice. Life Sci 2003; 74:543-552.
20. Bonventre JV, Siegel N, Rosen S, et al. Acute renal failure. Relative importance of proximal vs distal tubular injury. Am J Physiol 1998; 275:623-631.
21. Sanger JW, Sanger JM. Differential response of three types of actin filament bundles to depletion of cellular ATP levels. Eur J Cell Biol 1983; 31:182-197.
22. Kroshian VM, Sheridan A, Lieberthal W. Functional and cytoskeletal changes induced by sublethal injury in proximal tubular epithelial cells. Am J Physiol 1994; 266:F21-F30.
23. Weinberg JM. The cell biology of ischemic renal injury. Kidney Int 1991; 39:476-500.
24. Warde AV, Stromski ME, Thulin G, et al. Protection of the kidney against ischaemic injury by inhibition of 5′-nucleotidase. Am J Physiol 1989; 256:F298-F302.
25. McCoy CE, Selvaggio AM, Alexander EA, Schwartz JH. Adenosine triphosphate depletion induces a rise in cytosolic free calcium in canine renal cells. J Clin Invest 1988; 82:1326-1332.
26. Nakamura H, Nemenoff R, Gronich J, Bonventre JV. Subcellular characteristics of phospholipase A2 activity in the rat kidney. J Clin Invest 1991; 87:1816-1818.
27. Bonventre JV. Mechanisms of ischaemic acute renal failure. Kidney Int 1993; 268:1609-1619.
28. Edelstein CL, Yaqoob MM, Alkhunaizi AM, et al. Modulation of hypoxia-induced calpain activity in rat renal proximal tubules. Kidney Int 1996; 50:1150-1157.
29. Lieberthal W, Koh JS, Levine JS. Necrosis and apoptosis in acute renal failure. Semin Nephrol 1998; 18:505-518.
30. Villa P, Kaufman SH, Earnshaw WC. Caspases and caspase inhibitors. Trends Biochem Sci 1997; 22:388-393.
31. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002; 11:301-308.
32. Guo R, Yang Y, Minto AW. Acute renal failure in endotoxemia is dependent on caspase activation. J Am Soc Nephrol 2004; 15:3093-3102.
33. Du C, Guan Q, Daio H, et al. Nitric oxide induces apoptosis in renal tubular epithelial cells (TEC) through activation of caspase-8. Am J Physiol Renal Physiol 2005 [Epub ahead of print].
34. Sharples JE, Patel N, Brown B, et al. Erythropoietin protects the kidney against injury and dysfunction caused by ischaemia-reperfusion. J Am Soc Nephrol 2004; 15:2115-2124.
35. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of NF-κβ activation with antioxidants is correlated with reduced cytokine transcription in PTC. Am J Physiol 1999; 277:F779-F789.
36. Lee TL, Ota-Setlik A, Fu Y, et al. Differential protective effects of volatile anaesthetics against renal ischaemia reperfusion injury in vivo. Anaesthesiology 2004; 101:1313-1324.
37. Cittanova ML. Is perioperative renal dysfunction of no consequence? Br J Anaesth 2001; 86:164-166.
38. Kellen M, Aronson A, Roizen MF, et al. Predictive and diagnostic tests of acute renal failure: a review. Anesth Analg 1994; 78:134-142.
39. Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006; 17:254-261 [Epub ahead of print].
40. Sear JW. Kidney dysfunction in the post operative period. Br J Anaesth 2005; 95:20-32.
41. Dharnidharka VR, Kwon C, Stephens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221-226.
42. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal disease. J Am Soc Nephrol 2004; 15:1677-1689.
43. Molls RR, Savransky V, Liu M, et al. Keratinocyte-derived chemokine is an early biomarker in acute kidney injury. Am J Physiol Renal Physiol 2005 [Epub ahead of print].
44. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase associated lipocalin as a novel early urinary biomarker for ischaemic renal injury. J Am Soc Nephrol 2003; 14:2534-2543.
45. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231-1238. The authors studied 71 children undergoing cardiac surgery. Urine and serum NGAL represent sensitive, specific and highly predictive biomarkers of ARF following cardiac surgery.
46. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation 1. Effects of diuretics. Am J Physiol 1994; 267:F1059-F1062.
47. Mehta RL, Pascaul MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. J Am Med Assoc 2002; 288:2547-2553.
48. Bellomo R, Chapman M, Finfer S, et al. Low dose dopamine in patients with early renal dysfunction: a placebo controlled randomised trial. Lancet 2000; 356:2139-2143.
49. Goetz KL. Physiology and pathophysiology of atrial peptides. Am J Physiol 1998; 254:E1-E15.
50. Conger JD, Falk SA, Yuan BH, et al. Atrial natriuretic peptide and dopamine in a rat model of ischaemic acute renal failure. Kidney Int 1989; 35:1126-1132.
51. Nakamoto M, Shapiro JI, Shanley PF, et al. In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. J Clin Invest 1987; 80:698-705.
52. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischaemic acute renal failure. A randomised placebo controlled trial. Crit Care Med 2004; 32:1310-1315.
53. Kellum JA, Leblanc M, Gibney N, et al. Primary prevention of acute renal failure in the critically ill. Curr Opin Crit Care 2005; 11:537-541. This review again highlights that, at present, non-pharmacologic strategies are more effective than drugs at reducing the risk of ARF in the critically ill patient.
54. Halpenny M, Lakshmi S, O'Donnell A, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 2001; 56:953-960.
55. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aorta repair. Eur J Anaesth 2002; 19:32-39.
56. Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomised, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005; 46:26-34.
57. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery. A prospective placebo controlled trial. Circulation 2005; 110:3230-3235. The authors compared fenoldopam to low-dose dopamine infusion in 80 postoperative cardiac surgery patients. No difference was seen in the incidence of ARF between the two groups (defined as a rise in serum baseline creatinine greater than 25%).
58. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. Circulation 1986; 74:1124-1136.
59. Cohen MV, Baines CP, Downey JM. Ischaemic preconditioning: from adenosine receptor of KATP channel. Annu Rev Physiol 2000; 62:79-109.
60. Hashiguchi H, Morooka H, Miyoshi H, et al. Isoflurane protects renal function against ischaemia and reperfusion through inhibition of protein kinases, JNK and ERK. Anesth Analg 2005; 101:1584-1589. This laboratory study investigated the effect of preconditioning with 1.5% isoflurane for 20 min before ischaemia in a rat model. The activities of the stress protein kinases, JNK and ERK but not p38, were significantly less in the kidneys of the preconditioning group.
61. Julier K, Da Silva R, Garcia C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double blind place-controlled multi-centre study. Anaesthesiology 2003; 96:1315-1327.
62. Devarajan P, Mishra J, Supavekin S, et al. Gene expression in early renal injury: clues towards pathogenesis, biomarker discovery and novel therapeutics. Mol Gen Metab 2003; 80:365-376.
63. Ouellette AJ, Malt RA, Sukhatme VP, Bonventre JV. Expression of two immediate early genes, Egr-1 and c-fos, in response to renal ischaemia and during renal hypertrophy in mice. J Clin Invest 1990; 85:766-777.
64. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003; 14 (Suppl. 1):S55-S61.
65. Andersson G, Jennische E. IGF-1 immunoreactivity is expressed by regenerating renal tubular cells after ischaemic injury in the rat. Acta Physiol Scand 1998; 132:453-457.
66. Hirschberg R, Kopple J, Lipsett P. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55:2423-2432.
67. Hladunewich MA, Corrigan G, Derby GC. A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study post-ischemic ARF. Kidney Int 2003; 64:593-602.
68. Poulsom R, Forbes SJ, Hodivala-Dilke K, et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001; 195:229-235.
69. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischaemic acute renal failure through differentiation- independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31-F42.
70. Imai E. Gene therapy for renal diseases: its potential and limitation. Am Soc Nephrol 2003; 14:1102-1104.
71. Tsujie M, Isaka Y, Nakamura H, et al. Electroporation-mediated gene transfer that targets glomeruli. J Am Soc Nephrol 2001; 12:949-954.
72. Chen S, Agarwal A, Glushakova OY, et al. Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors. J Am Soc Nephrol 2003; 14:947-958.
73. Franquesa M, Alperovich G, Herrero-Fresneda I, et al. Direct electrotransfer of hHGF gene into kidney ameliorates ischaemic acute renal failure. Gene Ther 2005; 12:1551-1558.